Atas, NuhCaliskan, Ali RizaAkatli, Aysenur2026-04-042026-04-0420242472-5625https://doi.org/10.1093/mrcr/rxae050https://hdl.handle.net/11616/109181Polymyalgia rheumatic (PMR) associated amyloidosis is an extremely rare condition that can be rapidly progressive with high morbidity and mortality and management is challenging. Tocilizumab is a monoclonal anti-IL-6 receptor antibody, which is in the therapeutic arsenal of PMR. The efficiency of tocilizumab in improvement of PMR activity score and decreasing steroid dose is well-established, while efficiency in PMR-associated amyloidosis has not been published. Herein, we reported a PMR patient with amyloid A amyloidosis who was treated effectively with tocilizumab.eninfo:eu-repo/semantics/closedAccessPolymyalgia rheumaticaAA amyloidosistocilizumabIL-6proteinuriaArticle912142173918560410.1093/mrcr/rxae0502-s2.0-85215549852Q3WOS:001308839200001Q40000-0001-5880-4974